ARWR (Arrowhead Pharma) רווח למניה בשנים עשר החודשים האחרונים

The absence of commercial products and reliance on partner payments drive volatility, causing the annual EPS TTM trend to exhibit instability, with the current mark at -11527.80. Meanwhile, Arrowhead Pharmaceuticals (ARWR) maintains margins through its leadership in RNA interference and alliances with industry behemoths. Simultaneously, the company is implementing energy-saving systems and strict emission controls in its laboratories to comply with ESG standards.
ARWR (Arrowhead Pharmaceuticals): פילוחים אנליטיים ודוחות לפי אינדיקטורים

For Arrowhead Pharmaceuticals (ARWR), whose potential depends on the commercialization of RNAi therapy, the YoY TTM earnings per share dynamics reflect the efficiency of the transition from development to sales. This indicator measures the percentage change in net income per share over the last twelve months relative to the previous year, allowing investors to detect trend reversals and assess the risk of asset overvaluation should results deviate from expectations.